ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

PTIX Protagenic Therapeutics Inc

1.61
-0.21 (-11.54%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 9,049
Bid Price 1.61
Ask Price 1.87
News -
Day High 1.8393

Low
0.6797

52 Week Range

High
2.32

Day Low 1.68
Company Name Stock Ticker Symbol Market Type
Protagenic Therapeutics Inc PTIX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.21 -11.54% 1.61 20:00:00
Open Price Low Price High Price Close Price Prev Close
1.79 1.68 1.8393 1.75 1.82
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
84 9,049 $ 1.78 $ 16,102 - 0.6797 - 2.32
Last Trade Time Type Quantity Stock Price Currency
19:14:29 2 $ 1.78 USD

Protagenic Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
7.76M 4.44M - 0 -3.56M -0.80 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Protagenic Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No PTIX Message Board. Create One! See More Posts on PTIX Message Board See More Message Board Posts

Historical PTIX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.361.871.351.6920,2020.2518.38%
1 Month0.9851.870.881.3119,7920.62563.45%
3 Months0.88961.870.73361.209,7820.720480.98%
6 Months1.761.88540.67971.0612,592-0.15-8.52%
1 Year1.632.320.67971.319,020-0.02-1.23%
3 Years11.0019.560.679711.27456,421-9.39-85.36%
5 Years11.0019.560.679711.27456,421-9.39-85.36%

Protagenic Therapeutics Description

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Your Recent History

Delayed Upgrade Clock